RxDoctor Payments Data

Ronald Rasberry, MD

Family Medicine · Port St Lucie, FLNPI 1861888133

Payments from drug & device makers

$5,343in general payments, 2019–2025

Across 54 payments — averaging $98.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$715
  • Amgen$486
  • AbbVie$327
  • Lilly USA, LLC$315
  • plus $801 from 8 others

What the payments were for

  • Food & beverage$5,27799%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,343 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$113,738
Medicare patients
639
Services billed
2,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$96,730
XareltoRivaroxaban89$90,740
EliquisApixaban81$75,807
JanuviaSitagliptin Phosphate38$48,217
JardianceEmpagliflozin34$37,233
TrulicityDulaglutide27$32,517
JanumetSitagliptin Phos/Metformin Hcl16$26,160
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,844
Breo ElliptaFluticasone/Vilanterol27$16,860
MounjaroTirzepatide11$11,163
RybelsusSemaglutide13$10,791
Levothyroxine Sodium561$5,691
Atorvastatin Calcium600$5,399
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,106
Rosuvastatin Calcium416$4,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,188$107,52180 claims
Johnson & JohnsonXarelto$122$90,74089 claims
PfizerEliquis, Paxlovid$12$77,17793 claims
MerckJanuvia, Janumet$125$74,37754 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$715$43,81065 claims
Lilly USA, LLCTrulicity, Mounjaro$315$43,68038 claims
AstraZenecaSymbicort$1,510$3,63914 claims
AbbVieSynthroid$327$3,47443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →